Cohortias

Executive Summary

Cohortias is a Mexico City-based contract research organization (CRO) founded in 2015, providing clinical trial services across oncology, infectious disease, and cardiovascular therapeutic areas. With a team of 50-200 employees, the company serves as a platform for clinical research, leveraging Mexico's competitive cost environment and growing clinical trial infrastructure. As a private company with no disclosed funding, Cohortias is positioned to benefit from the increasing trend of pharmaceutical companies outsourcing clinical trials to emerging markets. Its focus on multiple high-demand therapeutic areas aligns with global R&D priorities, particularly in oncology and infectious diseases. The company's estimated valuation and lack of public financials suggest a cautious growth trajectory, but its presence in Latin America's largest clinical trial hub offers potential for steady contract wins and regional expansion.

Upcoming Catalysts (preview)

• Q4 2026Expansion of clinical trial services into new Latin American markets65% success
• Q2 2027Strategic partnership with a major pharmaceutical company for oncology trials50% success
• Q3 2026Receipt of a significant government or private research grant to enhance capabilities40% success